Mesa Laboratories (MLAB) Expected to Announce Earnings on Wednesday

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) will likely be posting its Q4 2025 quarterly earnings results before the market opens on Wednesday, May 28th. Analysts expect Mesa Laboratories to post earnings of $2.75 per share and revenue of $61.90 million for the quarter.

Mesa Laboratories Trading Up 1.5%

Shares of MLAB stock traded up $1.57 on Thursday, hitting $104.64. The stock had a trading volume of 52,455 shares, compared to its average volume of 40,208. The company's 50 day moving average price is $115.72 and its 200-day moving average price is $126.11. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.71 and a quick ratio of 0.53. Mesa Laboratories has a 1 year low of $83.68 and a 1 year high of $155.12. The firm has a market capitalization of $568.61 million, a P/E ratio of -2.26 and a beta of 0.97.

Mesa Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 16th. Investors of record on Friday, May 30th will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.61%. The ex-dividend date is Friday, May 30th. Mesa Laboratories's dividend payout ratio is currently -1.38%.

Insider Buying and Selling

In related news, CEO Gary M. Owens sold 21,000 shares of Mesa Laboratories stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $123.91, for a total transaction of $2,602,110.00. Following the transaction, the chief executive officer now owns 43,337 shares in the company, valued at approximately $5,369,887.67. The trade was a 32.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 4.40% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its holdings in Mesa Laboratories by 1.2% during the first quarter. Royal Bank of Canada now owns 30,772 shares of the medical instruments supplier's stock worth $3,652,000 after purchasing an additional 353 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Mesa Laboratories by 3.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 19,977 shares of the medical instruments supplier's stock valued at $2,370,000 after buying an additional 685 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Mesa Laboratories by 4.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier's stock valued at $364,000 after buying an additional 143 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new position in Mesa Laboratories during the first quarter valued at about $335,000. 90.60% of the stock is currently owned by institutional investors.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.